AbbVie (ABBV) said Monday its late-stage trial evaluating a subcutaneous induction treatment of Skyrizi in adults with active Crohn's disease met its co-primary efficacy endpoints at week 12.
The study showed 55% of patients receiving the drug achieved clinical remission and 44% reached an endoscopic response, compared with 30% and 14% for the placebo group, respectively, the company said.
The trial enrolled a predominantly treatment-resistant population and demonstrated a safety profile consistent with the medication's known risks, with serious adverse events occurring in 0.5% of treated patients versus 3.1% on placebo, AbbVie said.
The company also said the complete results will be shared at a later date.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.